BRAF Mutant Gastrointestinal Stromal Tumor: First report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance

Activating oncogenic mutations of BRAF have been described in patients with gastrointestinal stromal tumor (GIST), but treatment of GIST with BRAF inhibitors and mechanisms of mediating the emergence of resistance in GIST have not been reported. Dabrafenib is a potent ATP-competitive inhibitor of BR...

Descripción completa

Detalles Bibliográficos
Autores principales: Falchook, G.S., Trent, J.C., Heinrich, M.C, Beadling, C., Patterson, J., Bastida, C.C., Blackman, S.C., Kurzrock, R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2013
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3712576/
https://www.ncbi.nlm.nih.gov/pubmed/23470635

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3712576/
https://www.ncbi.nlm.nih.gov/pubmed/23470635

Ejemplares similares